Login / Signup

SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system.

Benedetta Maria BonoraEmanuel RaschiAngelo AvogaroGian Poalo Fadini
Published in: Cardiovascular diabetology (2021)
In a large pharmacovigilance database, AF was robustly and consistently reported more frequently for diabetes medications other than SGLT2i. This finding complements available evidence from trials supporting a protective role of SGLT2i against the occurrence of AF.
Keyphrases